FDA, OVRR: August 2009-present; Influenza vaccine development. FDA, OBRR: March 2006- August 2009; Virology of coronaviruses and flaviviruses. University of Maryland: January 2002-February 2006; Viral reprograming of ribosomes. University of Medicine NJ: Sept 2000-December 2001; Frameshift signals in HIV. University of Otago, New Zealand: Ph.D. (Biochemistry) 2000; Retrotransposons in yeast.
Part of the book: Viral Genomes
Part of the book: Current Issues in Molecular Virology
For almost half a century, Sanger sequencing has been the conventional method for sequencing DNA. However, its utility for sequencing heterogeneous viral populations is limited because it can only detect mutations that are present in a significant portion of the DNA molecules. Several molecular methods that quantify mutations present at low levels in viral populations were proposed for evaluation of genetic consistency of viral vaccines; however, these methods are only suitable for single site polymorphisms, and cannot be used to screen for unknown mutations.
Part of the book: Steps Forwards in Diagnosing and Controlling Influenza